Related Experiment Video
Updated: Jun 3, 2026

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
Vascular remodeling and arterial calcification are directly mediated by S100A12 (EN-RAGE) in chronic kidney disease
Joseph Gawdzik1, Liby Mathew, Gene Kim
1Sections of Cardiology, Department of Medicine, University of Chicago, IL 60637, USA.
Insights
The proinflammatory cytokine S100A12 (EN-RAGE) promotes vascular calcification in chronic kidney disease (CKD). This study shows S100A12 exacerbates CKD-induced vascular osteogenesis and calcification in mice via RAGE activation and oxidative stress.
Area of Science:
- Cardiovascular Biology
- Nephrology
- Vascular Biology
Background:
- The proinflammatory cytokine S100A12 (EN-RAGE) is linked to cardiovascular issues in hemodialysis patients.
- This study investigates S100A12's role in vascular disease development under chronic kidney disease (CKD) conditions.
Purpose of the Study:
- To test if S100A12 expression in vascular smooth muscle contributes to vascular disease in a CKD mouse model.
- To elucidate the mechanisms by which S100A12 influences vascular calcification in CKD.
Main Methods:
- Chronic kidney disease (CKD) was induced in S100A12 transgenic and wild-type mice via ureter ligation.
- Aortic tissues and cultured aortic smooth muscle cells were analyzed after 7 weeks of elevated blood urea nitrogen (BUN).
Main Results:
- S100A12 transgenic mice exhibited enhanced vascular medial calcification compared to wild-type mice with CKD.
- Vascular calcification involved the S100A12 receptor, RAGE (receptor for advanced glycation endproducts), and oxidative stress.
- Inhibiting NADPH-oxidase Nox1 or RAGE signaling attenuated calcification and osteoblastic gene expression in cultured cells.
Conclusions:
- S100A12 significantly augments CKD-triggered vascular osteogenesis in mice.
- These findings mirror vascular calcification observed in human CKD and end-stage kidney disease patients.
Background:
The proinflammatory cytokine S100A12 (also known as EN-RAGE) is associated with cardiovascular morbidity and mortality in hemodialysis patients. In the current study, we tested the hypothesis that S100A12 expressed in vascular smooth muscle in nonatherosclerosis-prone C57BL/6J mice on normal rodent chow diet, but exposed to the metabolic changes of chronic kidney disease (CKD), would develop vascular disease resembling that observed in patients with CKD.
Methods:
CKD was induced in S100A12 transgenic mice and wild-type littermate mice not expressing human S100A12 by surgical ligation of the ureters. The aorta was analyzed after 7 weeks of elevated BUN (blood urea nitrogen), and cultured aortic smooth muscle cells were studied.
Results:
We found enhanced vascular medial calcification in S100A12tg mice subjected to CKD. Vascular calcification was mediated, at least in part, by activation of the receptor for S100A12, RAGE (receptor for advanced glycation endproducts), and by enhanced oxidative stress, since inhibition of NADPH-oxidase Nox1 and limited access of S100A12 to RAGE attenuated the calcification and gene expression of osteoblastic genes in cultured vascular smooth muscle cells.
Conclusion:
S100A12 augments CKD-triggered osteogenesis in murine vasculature, reminiscent of features associated with enhanced vascular calcification in patients with chronic and end-stage kidney disease.
Related Concept Videos
Atherosclerosis I: Introduction
Osteoclasts in Bone Remodeling
Chronic Kidney Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Chronic Kidney Disease II: Clinical Manifestations
Diabetic Nephropathy

